Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) has received Emergency Use Authorization (EUA) from the FDA for a new molecular diagnostic test that detects both SARS-CoV-2 and Influenza A+B within 2-3 hours. This test is designed to identify variants from the U.K. and South Africa, with 99.9% match to genetic sequences of these variants. The BD SARS-CoV-2/Flu assay operates on the BD MAX™ System, a platform that can analyze hundreds of samples daily. The product is now available in the U.S. and Europe as part of BD's ongoing response to COVID-19.
BD (Becton, Dickinson and Company) reported first fiscal quarter revenues of $5.315 billion, a 25.8% increase year-over-year, driven by $867 million from COVID-19 diagnostics. Diluted EPS rose to $3.35, up 285.1% from the previous year. The BD Medical segment saw revenues of $2.261 billion, while BD Life Sciences grew to $1.979 billion, reflecting significant COVID-19 contributions. BD expects fiscal 2021 revenue growth of 12% to 14% and adjusted EPS of $12.75 to $12.85, indicating robust financial momentum.
BD (Becton, Dickinson and Company) announced positive outcomes from the CLEAN3 trial, demonstrating that its vascular care solution significantly reduces peripheral intravenous catheter (PIVC) failures, showing rates of 34.8% versus 47.5% in the control group. The trial observed enhanced performance regarding antiseptics, with catheter colonization at 0.9% compared to 16.9%. Conducted at Poitiers University Hospital, France, the study involved around 1,000 patients, highlighting the benefits of BD’s integrated solution for improving patient safety and reducing hospital costs.
On January 26, 2021, BD (Becton, Dickinson and Company) announced that Tom Polen, current CEO, will also become chairman of the board effective April 28, 2021. He succeeds Vincent A. Forlenza, retiring after leading BD through significant transformations. Under Polen's leadership, BD expanded its role during the COVID-19 pandemic by enhancing diagnostic testing and manufacturing essential medical supplies. Polen, with over 20 years at BD, aims to drive the BD 2025 strategy focused on growth, simplification, and empowerment to improve global healthcare delivery.
The Board of Directors of BD (Becton, Dickinson and Company) has announced a quarterly dividend of $0.83 per share, payable on March 31, 2021, to shareholders on record as of March 10, 2021. This marks an annual dividend rate of $3.32 per share. BD is a leading global medical technology company focused on enhancing health care delivery and improving medical diagnostics through innovative solutions, impacting health outcomes globally.
BD (Becton, Dickinson and Company) has published a peer-reviewed study indicating that its antigen test may be more effective than PCR tests in identifying contagious COVID-19 patients. Analyzing 38 PCR-positive specimens, the antigen test showed 27 were indeed contagious, while 10 of the PCR results suggested non-infectious individuals. This suggests the BD Veritor™ Plus System could enhance public health responses during the pandemic. Published in Clinical Infectious Diseases on January 22, 2021, the study emphasizes the potential of antigen testing to contain COVID-19 spread effectively.
BD (Becton, Dickinson and Company) reported preliminary financial results for Q1 fiscal 2021, with revenues expected to be $5.3 billion, a 25.6% increase year-over-year. This growth was driven by strong demand for COVID-19 diagnostics, particularly the BD Veritor™ tests. The BD Life Sciences segment saw a 76.3% revenue increase, attributed to COVID-19 testing. The company expects to finalize its financial results by February 4, 2021, with updates anticipated during the J.P. Morgan Healthcare Conference on January 12, 2021.
BD (Becton, Dickinson and Company) will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast on January 12, 2021, at 7:30 a.m. Eastern Time. Investors can access the live presentation on the company's corporate website, with a replay available until January 19, 2021. BD is a leading global medical technology company dedicated to enhancing health through innovative technologies and solutions. With 65,000 employees worldwide, BD focuses on advancing clinical therapy, improving diagnostic accuracy, and addressing global health challenges.
BD (Becton, Dickinson and Company) has received pandemic orders exceeding 1 billion injection devices, including needles and syringes, to assist with COVID-19 vaccination globally. Shipments of over 300 million devices have already begun, with remaining orders scheduled for delivery through 2021. The company is also investing $1.2 billion over four years to enhance manufacturing capacity for pre-fillable syringes. BD collaborates with various governments to ensure vaccination readiness and has supplied millions of diagnostic products for COVID-19 treatment.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced successful results from a 52-subject clinical trial of the BD Libertas™ Wearable Injector, designed for subcutaneous delivery of biologics. The device effectively administered 5 mL of 8 cP injections with no severe adverse reactions, showcasing high patient acceptance. All participants expressed willingness to use the device if prescribed. This marks a significant advancement in drug delivery technology, especially for larger volume biologics, as BD aims to support pharmaceutical partners in developing innovative therapies.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
